Salbutamol: 6 agencies, 2007–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused salbutamol: all 14 decisive outcomes across 5 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 18.8 years separate the first record, 12 Sep 2007 at HAS (France), from the most recent, 17 Jun 2026 at CIPM (Spain).
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 3 of 15 records date from 2023 or later.
4 distinct indication wordings are recorded for salbutamol by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 15 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess salbutamol, on 12 Sep 2007; CIPM (Spain) did not open a file until 26 Mar 2025 — an unusually long tail of 17.5 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 12 years in total.
3 of the 6 agencies here assessed salbutamol more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for salbutamol.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 26 Mar 2025 | Indicación terapéutica autorizada: Alivio del broncoespasmo severo y tratamiento del “status asmaticus”. La utilización … | financed by the SNS · art. 92 a, d, e | source |
| HAS (France) | 11 Dec 2024 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2019 | Asthma and chronic obstructive pulmonary disease (COPD) | The PBAC recommended the Unrestricted Benefit listing of salbutamol, in the form of pressu… | source |
| CONITEC (Brazil) | 26 Sep 2012 | Tratamento da doença pulmonar obstrutiva crônica. | incorporated into SUS | source |
| SMC (Scotland) | 13 Oct 2008 | For patients aged six years and over with reversible airways obstruction, such as asthma, for the relief and prevention of asthma symptoms | accepted | source |
10 further decisions for salbutamol, across 4 agencies, are not shown here. They include the most recent record on file, 17 Jun 2026 from CIPM (Spain); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- budesonide / formoterol — same ATC class R03A — Obstructive airway diseases
- formoterol — same ATC class R03A — Obstructive airway diseases
- indacaterol — same ATC class R03A — Obstructive airway diseases
- terbutaline — same ATC class R03A — Obstructive airway diseases
- fluticasone / salmeterol — same ATC class R03A — Obstructive airway diseases
- olodaterol / tiotropium — same ATC class R03A — Obstructive airway diseases
Coverage: 15 decisions for salbutamol from 6 agencies, 2007 to 2026. Data to 7 Sep 2026. ATC class R03A — Obstructive airway diseases. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.